FDA Approves Sunovion Schizophrenia Drug

Xconomy Boston — 

Marlborough, MA-based drugmaker Sunovion Pharmaceuticals has announced that the FDA approved its once-daily, oral tablet for treating schizophrenia. The drug, Latuda (lurasidone HCl), is expected to be available in the U.S. early next year, Sunovion said. The drug company has six other FDA-approved drugs, including the insomnia treatment Lunesta; Omnaris, a nasal spray for treating allergy symptoms; and a number of inhalant drugs for treating asthma.